122 related articles for article (PubMed ID: 28222958)
1. Early-stage Favourable Anal Cancer: A Retrospective Analysis of Clinical Outcomes of a Moderately Low Dose Elective Nodal Intensity-modulated Radiotherapy Schedule.
Lestrade L; Zilli T; Kountouri M; Jumeau R; Matzinger O; Bourhis J; Miralbell R; Ozsahin M; De Bari B
Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):e105-e109. PubMed ID: 28222958
[TBL] [Abstract][Full Text] [Related]
2. Organ-sparing Intensity-modulated radiotherapy for anal cancer using the ACTII schedule: a comparison of conventional and intensity-modulated radiotherapy plans.
Brooks CJ; Lee YK; Aitken K; Hansen VN; Tait DM; Hawkins MA
Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):155-61. PubMed ID: 22981970
[TBL] [Abstract][Full Text] [Related]
3. Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer.
Ng M; Leong T; Chander S; Chu J; Kneebone A; Carroll S; Wiltshire K; Ngan S; Kachnic L
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1455-62. PubMed ID: 22401917
[TBL] [Abstract][Full Text] [Related]
4. High-tailored Anal Canal Radiotherapy (HIT-ART): Outcomes of a 10-Year Single Center Clinical Experience.
Manfrida S; Fionda B; Mariani S; Luca V; Bertolini R; Barbaro B; Chiloiro G; Frascino V; Tagliaferri L; Gambacorta MA
In Vivo; 2024; 38(3):1306-1315. PubMed ID: 38688632
[TBL] [Abstract][Full Text] [Related]
5. Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions.
Yates A; Carroll S; Kneebone A; Tse R; Horvath L; Byrne C; Solomon M; Hruby G
Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):700-7. PubMed ID: 26382849
[TBL] [Abstract][Full Text] [Related]
6. Modern intensity-modulated radiotherapy with image guidance allows low toxicity rates and good local control in chemoradiotherapy for anal cancer patients.
De Bari B; Lestrade L; Franzetti-Pellanda A; Jumeau R; Biggiogero M; Kountouri M; Matzinger O; Miralbell R; Bourhis J; Ozsahin M; Zilli T
J Cancer Res Clin Oncol; 2018 Apr; 144(4):781-789. PubMed ID: 29441419
[TBL] [Abstract][Full Text] [Related]
7. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal.
Tomasoa NB; Meulendijks D; Nijkamp J; Cats A; Dewit L
Acta Oncol; 2016 Jun; 55(6):760-6. PubMed ID: 26878244
[TBL] [Abstract][Full Text] [Related]
9. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
[TBL] [Abstract][Full Text] [Related]
10. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
Wright JL; Patil SM; Temple LK; Minsky BD; Saltz LB; Goodman KA
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1064-72. PubMed ID: 20350793
[TBL] [Abstract][Full Text] [Related]
11. [Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
Troussier I; Huguet F; Servagi-Vernat S; Benahim C; Khalifa J; Darmon I; Ortholan C; Krebs L; Dejean C; Fenoglietto P; Vieillot S; Bensadoun RJ; Thariat J
Cancer Radiother; 2015 Apr; 19(2):127-38. PubMed ID: 25770884
[TBL] [Abstract][Full Text] [Related]
12. Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
Yeung R; McConnell Y; Warkentin H; Graham D; Warkentin B; Joseph K; Doll CM
Radiat Oncol; 2015 Apr; 10():92. PubMed ID: 25903798
[TBL] [Abstract][Full Text] [Related]
13. Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
Anticancer Res; 2016 Apr; 36(4):1943-8. PubMed ID: 27069184
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of helical tomotherapy with daily image guidance in anal canal cancer patients.
De Bari B; Jumeau R; Bouchaab H; Vallet V; Matzinger O; Troussier I; Mirimanoff RO; Wagner AD; Hanhloser D; Bourhis J; Ozsahin EM
Acta Oncol; 2016 Jun; 55(6):767-73. PubMed ID: 27034083
[TBL] [Abstract][Full Text] [Related]
15. Genital invasion or perigenital spread may pose a risk of marginal misses for Intensity Modulated Radiotherapy (IMRT) in anal cancer.
Koeck J; Lohr F; Buergy D; Büsing K; Trunk MJ; Wenz F; Mai S
Radiat Oncol; 2016 Apr; 11():53. PubMed ID: 27044498
[TBL] [Abstract][Full Text] [Related]
16. Inguinal lymph node recurrence in the untreated groin of patients with anal carcinoma.
Blinde SE; Schasfoort R; Mens JW; Verhoef C; Olofsen M; Nuyttens JJ
Dis Colon Rectum; 2014 May; 57(5):578-84. PubMed ID: 24819097
[TBL] [Abstract][Full Text] [Related]
17. Modeling early haematologic adverse events in conformal and intensity-modulated pelvic radiotherapy in anal cancer.
Robinson M; Sabbagh A; Muirhead R; Durrant L; Van den Heuvel F; Hawkins M
Radiother Oncol; 2015 Nov; 117(2):246-51. PubMed ID: 26409831
[TBL] [Abstract][Full Text] [Related]
18. [Anal channel cancer: customization of dose, volume and breaching].
Peiffert D
Cancer Radiother; 2019 Oct; 23(6-7):773-777. PubMed ID: 31471250
[TBL] [Abstract][Full Text] [Related]
19. [Anal canal cancer: In the era of intensity-modulated radiotherapy, outstanding issues].
Peiffert D; Baumann AS; Serre AA; Vendrely V; Rouard N; Faivre JC; Vogin G
Cancer Radiother; 2018 Oct; 22(6-7):509-514. PubMed ID: 30181029
[TBL] [Abstract][Full Text] [Related]
20. The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer.
Saarilahti K; Arponen P; Vaalavirta L; Tenhunen M
Radiother Oncol; 2008 Jun; 87(3):383-90. PubMed ID: 18501454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
